Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Intra-Cellular Therapies' latest earnings results highlight a continued positive growth trajectory, driven primarily by the strong performance of its flagship drug, CAPLYTA (lumateperone).</li><li>The company reported $175.2 million in net sales for CAPLYTA during the third quarter of 2024, reflecting a notable 39% increase compared to the same period last year.</li><li>This growth outpaced the overall antipsychotic market, underscoring CAPLYTA's growing acceptance and market share, particularly in the treatment of bipolar depression.</li></ul>

Intra-Cellular Therapies' latest earnings results highlight a continued positive growth trajectory, driven primarily by the strong performance of its flagship drug, CAPLYTA (lumateperone).The company reported $175.2 million in net sales for CAPLYTA during the third quarter of 2024, reflecting a notable 39% increase compared to the same period last year.This growth outpaced the overall antipsychotic market, underscoring CAPLYTA's growing acceptance and market share, particularly in the treatment of bipolar depression.

Intra-Cellular Therapies: These Are 5 Critical Challenges Threatening Its Expansion Plans!

<ul><li>Intra-Cellular Therapies showcased robust financial and operational performance for the third quarter of 2024, spearheaded by the growth of their branded drug, CAPLYTA.</li><li>The company reported net sales of $175.2 million, marking a 39% increase compared to the third quarter of 2023.</li><li>This growth trajectory led Intra-Cellular Therapies to revise their 2024 full-year net sales guidance upward to between $665 million and $685 million.</li></ul>

Intra-Cellular Therapies showcased robust financial and operational performance for the third quarter of 2024, spearheaded by the growth of their branded drug, CAPLYTA.The company reported net sales of $175.2 million, marking a 39% increase compared to the third quarter of 2023.This growth trajectory led Intra-Cellular Therapies to revise their 2024 full-year net sales guidance upward to between $665 million and $685 million.

Intra-Cellular Therapies Inc.: An Analysis Of The Commercial Strategy and Market Expansion for CAPLYTA & Key Growth Drivers

<ul><li>Intra-Cellular Therapies reported robust financial and operational results for the second quarter of 2024, underpinned by significant growth in their primary product, CAPLYTA.</li><li>This performance highlights several positive developments and a few areas of consideration for potential investors.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Intra-Cellular Therapies reported robust financial and operational results for the second quarter of 2024, underpinned by significant growth in their primary product, CAPLYTA.This performance highlights several positive developments and a few areas of consideration for potential investors.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Intra-Cellular Therapies Inc.: Preparations for New Pipeline Developments and Indications! - Major Drivers

<ul><li>Intra-Cellular Therapies announced a robust performance in the first quarter of 2024, demonstrating notable advances in both the commercial and clinical realms.</li><li>The company reported a significant rise in total revenues, reaching $144.9 million with CAPLYTA net sales alone accounting for $144.8 million, reflecting a 53% growth year-over-year.</li><li>This growth trajectory reaffirms the drug’s strong market acceptance and penetration within its approved indications for bipolar depression and schizophrenia.</li></ul>

Intra-Cellular Therapies announced a robust performance in the first quarter of 2024, demonstrating notable advances in both the commercial and clinical realms.The company reported a significant rise in total revenues, reaching $144.9 million with CAPLYTA net sales alone accounting for $144.8 million, reflecting a 53% growth year-over-year.This growth trajectory reaffirms the drug’s strong market acceptance and penetration within its approved indications for bipolar depression and schizophrenia.

Intra-Cellular Therapies Inc.: How They Are Expanding Market Opportunities for CAPLYTA!  - Major Drivers

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>Semiconductors (SMH,SOXX,NVDA,AVGO) have been leadership since late-2022, but they're extended and starting to see profit taking as market participants rotate into other laggard areas of the market (especially Energy).</li>
<li>The question is whether this new trend lasts a few days, or if this is the start of longer-term trend.</li>
<li>If there will be any lasting rotation away from Technology/semiconductors, SPX and QQQ would need to break strong short-term supports at 5370-5380 and $468-469, respectively. Until then, Tech/semis remain leadership</li>
</ul>


Semiconductors (SMH,SOXX,NVDA,AVGO) have been leadership since late-2022, but they're extended and starting to see profit taking as market participants rotate into other laggard areas of the market (especially Energy).
The question is whether this new trend lasts a few days, or if this is the start of longer-term trend.
If there will be any lasting rotation away from Technology/semiconductors, SPX and QQQ would need to break strong short-term supports at 5370-5380 and $468-469, respectively. Until then, Tech/semis remain leadership


Rotation Is the Lifeblood of a Bull Market; Still Bullish; Supports at SPX 5370-5380, QQQ $468-469

United States

Intra-Cellular Therapies Inc. researches and develops biopharmaceutical drugs. The Company engages in the research and development of small molecule drugs to treat neuropsychiatric and neurological diseases and other disorders of the central nervous system. Intra-Cellular Therapies offers its products to the medical industry.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Iti Inc (ITCI US)

Intra-Cellular Therapies: These Are 5 Critical Challenges Threatening Its Expansion Plans!

Intra-Cellular Therapies' latest earnings results highlight a continued positive growth trajectory, driven primarily by the strong performance of...

Baptista Research

Intra-Cellular Therapies Inc.: An Analysis Of The Commercial Strategy and Market Expansion for CAPLYTA & Key Growth Drivers

Intra-Cellular Therapies showcased robust financial and operational performance for the third quarter of 2024, spearheaded by the growth of their...

Baptista Research

Intra-Cellular Therapies Inc.: Preparations for New Pipeline Developments and Indications! - Major Drivers

Intra-Cellular Therapies reported robust financial and operational results for the second quarter of 2024, underpinned by significant growth in...

Baptista Research

Intra-Cellular Therapies Inc.: How They Are Expanding Market Opportunities for CAPLYTA! - Major Drivers

Intra-Cellular Therapies announced a robust performance in the first quarter of 2024, demonstrating notable advances in both the commercial and...

Baptista Research

Rotation Is the Lifeblood of a Bull Market; Still Bullish; Supports at SPX 5370-5380, QQQ $468-469

Rotation is the Lifeblood of a Bull Market; Bullish Outlook Intact; Expecting Short-term Support at $SPX 5370-5380 and $QQQ $468-469 (20-day MAs...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)